Berek JS et al. Safety and dose modification for patients receiving niraparib. Ann Oncol 2018;29(8):1784-92. Abstract
Coleman RL et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;[Epub ahead of print]. Abstract
Coleman RL et al. ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Proc AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment 2017;Abstract PR06.
Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61. Abstract
Colombo PE et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 2014;89(2):207-16. Abstract
de Bono J et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 2017;7(6):620-9. Abstract
Domchek SM et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016;140(2):199-203. Abstract
Drew Y et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Proc SGO 2018;Abstract LBA4.
González Martin A et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 2019;152(1):53-60. Abstract
Gray HJ et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol 2018;148(3):507-14. Abstract
Konstantinopoulos PA et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) — Results from ROC cohort. ASCO 2018;Abstract 106.
Lancaster JM et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015;136(1):3-7. Abstract
Ledermann J et al. ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer. ESMO 2017;Abstract LBA40_PR.
Ledermann J et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol 2014;15(8):852-61. Abstract
Ledermann J et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92. Abstract
Lim JSJ, Tan DSP. Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors. Cancers (Basel) 2017;9(8):pii:E109. Abstract
Lu KH et al. American Society of Clinical Oncology expert statement: Collection and use of a cancer family history for oncology providers. J Clin Oncol 2014;32(8):833-40. Abstract
Lynce F, Isaacs C. How far do we go with genetic evaluation? Gene, panel, and tumor testing. Am Soc Clin Oncol Educ Book 2016;35:e72-8. Abstract
Mirza MR et al. A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. ESMO 2016;Abstract LBA3_PR.
Mirza MR et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375(22):2154-64. Abstract
Monk BJ et al. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study. Proc SGO 2019;Abstract 3.
Moore KN et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicenter, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636-48. Abstract
Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract
Moore KN et al. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). ASCO 2014;Abstract TPS5616.
Norquist BM et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2(4):482-90. Abstract
Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. Abstract
Oza AM et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 2017;147(2):267-75. Abstract
Penson RT et al. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. ASCO 2019;Abstract 5506.
Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274-84. Abstract
Pujade-Lauraine E et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study. Proc SGO 2017;Abstract LBA2.
Ray-Coquard IL et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. ESMO 2019;Abstract LBA2_PR.
Steffensen KD et al. Veliparib monotherapy to patients with BRCA germ line mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study. Int J Gynecol Cancer 2017;27(9):1842-9. Abstract